

This listing of claims will replace all prior versions, and listings, of claims in this application:

Listing of Claims:

Claims 1-29 (canceled)

Claim 30 (currently amended): A recombinant anti-integrin antibody, or an antigen binding fragment thereof, which ~~specifically~~ binds to the open conformer of an α L subset of LFA-1 integrin I-domain but not to ~~relative to~~ the closed conformer of an said α L subset of LFA-1 integrin I-domain

Claim 31-76 (canceled)

Claim 77 (currently amended): The antibody, or an antigen binding fragment thereof, of claim ~~25~~ or 30 84, wherein said antibody is a humanized antibody.

Claim 78 (currently amended): The antibody, or an antigen binding fragment thereof, of claim ~~25~~ or 30 84, wherein said antibody is a chimeric antibody.

Claim 79 (canceled)

Claim 80 (currently amended): The antibody, or antigen binding fragment thereof, of claim ~~25~~ 84, wherein said antibody, or antigen binding fragment thereof, is identified by screening a phage display library with a modified integrin polypeptide, and isolating said antibody, or antigen binding fragment thereof.

Claims 81-82 (canceled)

Claim 83 (currently amended): An antibody, or an antigen binding fragment thereof, which binds to an α L integrin I-domain in the open conformation but not to an α L integrin I-domain in the closed conformation, said antigen or fragment blocking the interaction between the integrin and a cognate

ligand selected from the group consisting of ICAM-1, ICAM-2 and ICAM-3.

Claim 84 (currently amended): An antibody, or an antigen binding fragment thereof, which binds to an integrin I-domain of an α L integrin, the I-domain being locked in the open conformation by the substitutions ~~E284C-E301C~~ E284C/E301C or ~~K287C-K294C~~ K287C/K294C ~~mutations~~ but not to a modified integrin I-domain that is locked in the closed conformation by the substitutions K289C/K294C.

Claim 85 (canceled)

Claim 86 (canceled)

Claim 87 (previously presented): The antibody, or antigen binding fragment thereof, of claim 84, wherein the I-domain in the open conformation comprises substitutions E284C/E301C in an α L subunit.

Claim 88 (previously presented): The antibody, or antigen binding fragment thereof, of claim 84, wherein the I-domain in the open conformation comprises substitutions K287C/K294C in an α L subunit.

Claims 89-104 (canceled)

Claims 105 (currently amended): The antibody, or antigen binding fragment thereof, of claim ~~84~~ 83 that is a monoclonal antibody..

Claims 106 (currently amended): The antibody, or antigen binding fragment thereof, of claim ~~84~~ 83 that is a recombinant antibody..

Claims 107-113 (canceled)

Claim 114 (currently amended): The antibody, or antigen binding fragment, of claim ~~25, 26, 30, 83~~ or 84 further comprising a physically linked detectable substance.

Claim 115 (currently amended): The antibody, or antigen binding fragment, of claim 114, wherein

the physically linked detectable substance comprises an enzyme, a fluorescent material, or a radioactive material.

Claims 116-127 (canceled)

Claim 128 (currently amended): A pharmaceutical composition comprising (i) an antibody or antigen binding fragment thereof according to claim ~~30, 83 or~~ 84, and (ii) a pharmaceutically acceptable carrier.

Claims 129-131 (canceled)

Claim 132 (currently amended): The antibody or an antigen binding fragment thereof of claim 30, wherein the open conformer is defined by the ~~E284C-E301C~~ E284C/E301C or ~~K287C-K294C~~ K287C/K294C mutations.

Claim 133 (currently amended): A recombinant antibody, or an antigen binding fragment thereof, which binds to an integrin I-domain of an α L integrin, the I-domain being locked in the open conformation by the substitutions ~~E284C-E301C~~ E284C/E301C but not to a modified α L integrin I-domain that is locked in the closed conformation by the substitutions K289C/K294C, wherein the antibody or antigen binding fragment thereof blocks interaction between LFA-1 and ICAM-1.

Claim 134 (currently amended): A recombinant antibody, or an antigen binding fragment thereof, which binds to an integrin I-domain of an α L integrin, the I-domain being locked in the open conformation by the substitutions ~~K287C-K294C~~ K287C/K294C but not to a modified α L integrin I-domain that is locked in the closed conformation by the substitutions K289C/K294C, wherein the antibody or antigen binding fragment thereof blocks interaction between LFA-1 and ICAM-1.